Abstract

Introduction

Left atrial (LA) enlargement is an important risk factor for incident stroke and a key determinant for the success of rhythm control strategies in patients with atrial fibrillation (AF). However, factors associated with LA volume in AF patients remain poorly understood.

Methods

Patients with paroxysmal or persistent AF were enrolled in this study. Real time 3-D echocardiography was performed in all participants and analyzed offline in a standardized manner. We performed stepwise backward linear regression analyses using a broad set of clinical parameters to determine independent correlates for 3-D LA volume.

Results

We included 210 patients (70.9% male, mean age 61±11 years). Paroxysmal and persistent AF were present in 95 (45%) and 115 (55%) patients, respectively. Overall, 115 (55%) had hypertension, 11 (5%) had diabetes, and 18 (9%) had ischemic heart disease. Mean indexed LA volume was 36±12 ml/m². In multivariable models, significant associations were found for female sex (β coefficient -10.51 (95% confidence interval (CI) -17.85;-3.16), p = 0.0053), undergoing cardioversion (β 11.95 (CI 5.15; 18.74), p = 0.0006), diabetes (β 14.23 (CI 2.36; 26.10), p = 0.019), body surface area (BSA) (β 34.21 (CI 19.30; 49.12), p<0.0001), glomerular filtration rate (β -0.21 (CI -0.36; -0.06), p = 0.0064) and plasma levels...
of NT-pro brain natriuretic peptide (NT-proBNP) (β 6.79 (CI 4.05; 9.52), p < 0.0001), but not age (p = 0.59) or hypertension (p = 0.42). Our final model explained 52% of the LA volume variability.

Conclusions

In patients with AF, the most important correlates with LA volume are sex, BSA, diabetes, renal function and NT-proBNP, but not age or hypertension. These results may help to refine rhythm control strategies in AF patients.

Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population, and its prevalence is expected to increase in the coming decades.[1,2] AF has an important impact on general health in affected patients, because of its close relationship with heart failure, stroke, cognitive dysfunction and death.[1,2]

The pathophysiology of AF is complex and incompletely understood, but atrial remodelling and fibrosis seem to play a key role.[1,3,4] The left atrium (LA) has a reservoir and conduit function, and is an important regulator of left ventricular filling.[3] It also reflects an important electrophysiological substrate and has neurohumoral properties by releasing natriuretic peptides.[3,5] Those factors are closely related to left ventricular systolic and diastolic function. [3,6] LA enlargement itself is an important risk factor for incident AF[6–10], and is related to an increased stroke risk.[6–12] LA size is also a key determinant for the success of rhythm control strategies in patients with AF.[3,4] In the general population without established cardiac diseases, various factors influencing the LA volume have been described, including age, body size, body mass index and elevated blood pressure.[3,6,9,12–14]

In contrast, little evidence is available on determinants of LA volume among patients with established AF. This is an important issue, given the increasing use of pharmacological treatments and interventional procedures to maintain sinus rhythm in AF patients, and the fact that these strategies have limited long-term success rates and significant risks.[15,16] Thus, an enhanced understanding of factors associated with LA enlargement and atrial remodeling in this patient population may help to refine these strategies and improve success rates. Consequently, we assessed independent determinants of LA volume in patients with AF undergoing interventions aiming to achieve sinus rhythm.

Methods

Study population

We analyzed consecutive patients with either paroxysmal or persistent AF, who were scheduled to undergo catheter ablation (CA) (n = 140) or electrical cardioversion (ECV) (n = 80) at a tertiary academic center in Switzerland between January 2010 and March 2012. Paroxysmal AF was defined as AF consisting of episodes, which spontaneously converted within 7 days, and persistent AF as AF with at least one episode lasting >7 days.[1] Patients needed to be older than 18 years, provide informed consent and AF had to be confirmed by Holter-ECG. We excluded patients with severe valvular disease qualifying for interventional or surgical treatment, unstable and acute heart failure, limiting active or chronic major diseases, and a history of open-heart surgery within 3 months before enrollment. The local ethics committee
Ethikkommission Nordwest- und Zentralschweiz (EKNZ) approved the study protocols. Each patient provided written informed consent. The study has been conducted according to the principles expressed in the Declaration of Helsinki. Due to consent form restrictions, data cannot be made publicly available and all analyses must be approved by the principal investigator.

Study procedures

Electrocardiographic evidence of AF was obtained from every participant. All patients had to have appropriate oral anticoagulation before, during and after CA or ECV. ECV and CA procedures were performed with patients under conscious sedation in conformity with local recommendations and clinical standards. An experienced echocardiographer acquired a real-time three-dimensional transthoracic echocardiogram (RT3DE) in all patients within 24 hours prior to the corresponding intervention. Of the 220 patients enrolled, 10 were excluded due to missing data, leaving 210 patients for the current analyses.

Assessment of clinical and blood parameters

Information about personal and medical factors was obtained using standardized questionnaires. Prior to the intervention, fasting venous blood samples were collected in EDTA containers, immediately centrifuged and stored at -80°C. Serum creatinine, cystatin C, high-sensitivity C-reactive protein, and interleukin 6 (IL-6) were measured on a Beckman Coulter Unicel DxC600 Synchro Clinical System (Beckman Coulter, California). High-sensitivity troponin T (cTnT) and N-terminal proB-type natriuretic peptide (NT-proBNP) were assessed on the Elecsys 2010 immunoassay analyzer (F. Hoffmann-La Roche, Switzerland). The body surface was estimated by using Du Bois’s equation (Body surface area (m²) = [Weight (kg)⁰.⁴₂₅ x height (m)⁰.₇₂₅] x 0.007184). The creatinine and cystatin C based chronic kidney disease epidemiology collaboration (CKD-EPI) formula was applied to estimate the glomerular filtration rate (eGFR).[17]

Echocardiographic image acquisition and quantification

Echocardiograms were performed by three dedicated cardiologists with an iE33 (Philips Medical Systems, Andover, MA) equipped with a X3-1 and X5-1 transducer. Two-dimensional cine-loops of the parasternal long and short axis, as well as of the apical two-, three- and four-chamber views were obtained in each patient. For RT3DE imaging, full volume loops were collected during breath-hold with gated acquisition, and with sector size and depth optimized to obtain the maximum possible frame rate. Gain settings were adjusted to enable specific adjustments during post-processing, if necessary. For LA volume assessment the image view was adapted if needed to achieve optimal delineation of LA structures, and the trigger delay was set to 300ms for coverage of the entire ventricular diastole. At least two RT3DE datasets were collected per patient and transferred to a workstation for offline analysis by a trained cardiologist using dedicated three-dimensional quantification software (4D-LA-analysis, TomTec-Imaging Systems, Unterschleissheim Munich, Germany).[18–20]

For RT3DE analysis of the LA, initial LA contours at end-diastole and end-systole were manually defined for the apical four-chamber, two-chamber, and long-axis views excluding the LA appendage and pulmonary veins.[18–20] The software then constructed a three-dimensional polyhedral model of the LA by an automated border detection approach and calculated the maximal (VMax [ml]) and minimal (VMin [ml]) LA volumes.[18–20]

All analyses were performed in a blinded fashion by two physicians (A.Z. and M.B.). Interobserver agreement was determined by using repeated VMax measurements from 10 randomly selected subjects 12 months after the first analysis, with a mean difference for VMax of 9±7ml.
Statistical analysis

All statistical analyses were done using SAS statistical software (version 9.4; Cary, NC). A p-value of <0.05 was pre-specified to indicate statistical significance. Baseline characteristics were stratified according to the underlying AF type. The distribution patterns for continuous variables were evaluated using kurtosis, skewness and visual inspection of the histogram. Continuous data were expressed as mean ± SD or median (interquartile range), categorical data as frequency (percentage). Normally distributed variables were compared using unpaired Student t-tests, otherwise Wilcoxon’s rank sum tests were used. Categorical variables were compared by Chi-square or Fisher’s exact tests, as appropriate. All analyses were performed using maximal absolute LA volume (Vmax) as a continuous variable (in mL). Categorical variables were entered in the multivariable models using binary indicator variables.

First, all continuous covariates were grouped into quartiles to assess the linearity of their relationship with Vmax in univariable linear regression models. Variables with non-linear associations were entered as categorical variables in the subsequent regression models. Second, stepwise backward linear regression analyses were performed to identify covariates independently associated with LA volume (Vmax), using a p-value <0.05 as a threshold to stay in the model. A list of 17 variables was used for this analysis, all of them being significantly associated with LA volume in the univariable models: Sex, age, cohort, AF type (paroxysmal versus persistent), arterial hypertension, diabetes, sleep apnea syndrome, history of heart failure, moderate or severe mitral regurgitation, body surface area, heart rate, IL-6, NT-proBNP, cTnT ≥15ng/L, eGFR, left ventricular mass and left ventricular ejection fraction. Third, subgroup analyses according to AF type were performed to evaluate consistency of the relationships between a set of independent covariates and LA volume. Formal differences across subgroups were assessed using multiplicative interaction terms in the non-stratified models.

Results

Mean age of the 210 patients enrolled was 61 years and 149 participants (70.9%) were male. Baseline characteristics according to AF type are presented in Table 1. Overall, 95 (45.2%) and 115 (54.8%) participants had paroxysmal and persistent AF, respectively. The median time from AF diagnosis was 1 year (interquartile range 1; 5). The mean absolute and indexed LA volumes were 72.2±26.8ml and 36.5±12.5ml/m², respectively. Patients with persistent AF were older and had more comorbidities, including a higher prevalence of hypertension, diabetes, ischemic heart disease, mitral regurgitation and history of valve replacement. Patients with paroxysmal AF had a lower heart rate, a lower diastolic blood pressure, lower levels of IL-6 and NT-proBNP and a higher eGFR. Left atrial enlargement defined as >34ml/m² was found in 105 (50%) patients.

Independent determinants of left atrial volume

Variables significantly associated with LA volume in univariable regression analyses are shown in the S1 Table. Using backward multivariable regression analyses, we found six independent factors associated with absolute LA volume, as illustrated in Fig 1. The strongest correlates of LA volume were body surface area (β-regression coefficient 7.71 per SD (95% confidence interval (CI) 4.35; 11.06)) and NT-proBNP (β 8.96 per SD (95% CI 5.35; 12.58), p for all <0.0001. Additionally, we found significant associations of LA volume with the female gender (β -10.51 (95% CI -17.85; -3.16), p = 0.0053) the ECV cohort (β 11.95 (95% CI 5.15; 18.74), p = 0.0006), diabetes (β 14.23 (95% CI 2.35; 26.10), p = 0.0191) and eGFR (β -4.06 per SD (95% CI -6.97; -1.15), p = 0.0064). The R² of our final multivariate model was 0.52, suggesting that our model captured 52% of the overall LA volume variability in our sample. To assess the cohort effect
among our models, we performed an additional multivariable analysis excluding this factor. This analysis revealed that persistent AF seems to be also an independent determinant of LA volume (p = 0.014), as shown in S1 Fig. Subgroup analyses stratified by AF type showed consistent associations of these risk factors with LA volume among those with paroxysmal and persistent AF (all p values for interaction = NS), as shown in Table 2.

Discussion

In patients with AF, assessment of LA dimensions is fundamental for follow-up and outcome prediction, including determination of arrhythmic freedom, quality of life and thromboembolic risk.[10] In order to define independent predictors of LA volume that may help to improve risk stratification in this context, we assessed LA volume with RT3DE in a large sample of patients with symptomatic AF. In a model that explained more than 50% of the LA volume variability, we found that LA volume was independently associated with sex, need for an

Table 1. Baseline characteristics according to underlying atrial fibrillation type.

|                      | Paroxysmal AF (n = 95) | Persistent AF (n = 115) | P-value*
|----------------------|------------------------|-------------------------|-----------
| Indexed left atrial volume (ml/m²) | 28 (24; 33)            | 42 (33; 50)             | <0.0001   |
| Age (years)          | 60 (54; 66)            | 65 (54; 71)             | 0.058     |
| Males (%)            | 63 (66.3)              | 86 (74.8)               | 0.18      |
| Heart rate (bpm)     | 60 (52; 68)            | 80 (71; 92)             | <0.0001   |
| Systolic blood pressure (mmHg) | 131 (120; 142)      | 134 (119; 149)          | 0.48      |
| Diastolic blood pressure (mmHg) | 80 (73; 87)            | 87 (73; 100)            | 0.007     |
| Body mass index (kg/m²) | 25.1 (23.6; 28.1)  | 27.4 (25.0; 30.5)       | 0.0002    |
| Body surface area (m²) | 1.96 (1.76; 2.08)    | 1.99 (1.84; 2.13)       | 0.027     |
| Arterial hypertension (%) | 44 (46.3)              | 71 (61.7)               | 0.025     |
| Diabetes mellitus (%) | 0 (0)                  | 11 (9.6)                | 0.002     |
| Ischemic heart disease (%) | 3 (3.2)                | 15 (13.0)               | 0.011     |
| History of heart failure (y/n) | 4 (4.2)                | 16 (13.9)               | 0.017     |
| Present moderate or severe MR (%) | 2 (2.1)               | 16 (13.9)               | 0.002     |
| History of valve replacement (%) | 0 (0)                  | 5 (4.4)                 | 0.039     |
| History of stroke (%) | 10 (10.5)              | 11 (9.6)                | 0.82      |
| Sleep apnea syndrome (%) | 2 (2.1)                | 13 (11.3)               | 0.010     |

Echocardiographic parameters:

|                      | Paroxysmal AF (n = 95) | Persistent AF (n = 115) | P-value*
|----------------------|------------------------|-------------------------|-----------
| LVEF (%)             | 55 (48; 59)            | 45 (35; 52)             | <0.0001   |
| Indexed LV mass (g/m²) | 89 (73; 107)           | 101 (83; 122)           | 0.0011    |

Laboratory parameters:

|                      | Paroxysmal AF (n = 95) | Persistent AF (n = 115) | P-value*
|----------------------|------------------------|-------------------------|-----------
| eGFR (ml/min1.73m²) | 92 (83; 104)           | 88 (73; 98)             | 0.003     |
| Interleukin 6 (pg/mL) | 1.65 (1.18; 2.46)     | 2.24 (1.65; 3.38)       | <0.0001   |
| NT-proBNP (pg/mL)   | 16.9 (9.5; 35.6)       | 114 (64; 181)           | <0.0001   |
| High-sensitivity TnT (ng/L) | 4.07 (1.50; 7.01) | 4.85 (1.50; 9.89)       | 0.086     |

Data are median (interquartile range) or number (percentage). LVEF = Left ventricular ejection fraction. LV = Left ventricular. eGFR = estimated glomerular filtration rate; bpm = Beat per minute; MR = Mitral regurgitation; NT-proBNP = N-terminal pro B-type natriuretic peptide; TnT = Troponin T.

* P values were based on student’s t-tests, Mann-Whitney U-tests or Chi-square tests, as appropriate.
† 37 patients with persistent atrial fibrillation were scheduled for pulmonary vein isolation.
‡ The body surface (m²) was estimated by applying Du Bois’ method.
¶ Includes any surgical valve replacement in the past.
§ Emphasizes any minor or major stroke in the past.
˚ The estimated glomerular filtration rate was calculated by using the creatinine and cystatine based CKD-EPI formula.

doi:10.1371/journal.pone.0164145.t001
ECV, presence of diabetes, BMI, NT-proBNP and renal function. To the best of our knowledge, this is one of the first studies to comprehensively assess determinants of LA volume in patients with manifest AF.

**Table 2. Subgroup analyses for independent determinants of left atrial volume stratified by atrial fibrillation type.**

| (n = 210) * | Left atrial volume (mL) |
|-------------|-------------------------|
| **Sex (y/n)** | β (95%CI) P for interaction |
| Paroxysmal AF | -7.12 (-16.12; -1.88) 0.66 |
| Persistent AF | -13.38 (-25.12; -1.65) |
| **Body surface area (m²), per SD** | |
| Paroxysmal AF | 9.17 (5.08; 13.26) 0.95 |
| Persistent AF | 8.36 (3.18; 13.55) |
| **NT-proBNP, log-unit (pg/mL), per SD †** | |
| Paroxysmal AF | 7.92 (3.58; 12.26) 0.18 |
| Persistent AF | 12.26 (5.58; 18.95) |
| **eGFR (ml/min1.73m²), per SD** | |
| Paroxysmal AF | -2.83 (-7.03; 1.36) 0.24 |
| Persistent AF | -4.06 (-9.17; 1.07) |

AF = Atrial fibrillation; y/n = yes / no; SD = Standard deviation; NT-proBNP = N-terminal-pro B-type natriuretic peptide; eGFR = Estimated glomerular filtration rate. The β (95% confidence intervals) represents the increase or decrease in left atrial volume (mL) per unit change of the specific covariate. The multivariable models included sex, body surface area, estimated glomerular filtration rate and N-terminal-pro B-type natriuretic peptide.

* Paroxysmal and persistent AF were found in 95 and 115 patients, respectively.
† Log-transformed variables.

**Fig 1. Independent determinants of left atrial volume in AF patients.** SE = Standard error; SD = Standard deviation; y/n = yes / no; ECV = Electrical cardioversion; NT-proBNP = N-terminal-pro B-type natriuretic peptide; eGFR = Estimated glomerular filtration rate. R² is reported for the final multivariable model. The β (95% confidence intervals) represents the increase or decrease in left atrial volume (mL) per unit change of the specific covariate. The multivariable model also included age, atrial fibrillation type (paroxysmal vs. persistent), resting heart rate, left ventricular ejection fraction, left ventricular mass, high-sensitivity troponin T ≥15ng/mL, interleukin-6, history of heart failure, arterial hypertension, moderate or severe mitral regurgitation and sleep apnea syndrome. All above presented variables selected by the stepwise backward regression model were significant at the ≤0.05 level. * log-transformed variables. † Estimated by the CKD-EPI formula including creatinine and cystatin C.

doi:10.1371/journal.pone.0164145.g001

doi:10.1371/journal.pone.0164145.t002
Our results show a substantially larger LA volume in male AF patients, confirming and expanding earlier data from healthy populations.\(^{[21]}\) Interestingly, the incidence of AF is lower in women than in men at every age group, which may be explained by the fact that a small LA may protect from developing AF.\(^{[12]}\) Further studies are needed to evaluate whether this finding is due to smaller body size in women or to true sex specific differences.

Body dimensions and diabetes are important metabolic risk factors for AF.\(^{[22–25]}\) The body dimensions, height and weight, have been shown to be a major determinant of LA size in the general population.\(^{[6,13,14]}\) Our study confirms the importance of obesity as a key risk factor for LA enlargement in patients with established AF. The interrelationships of body dimensions (e.g. body mass index), LA dimensions and incident AF have been shown previously.\(^{[12,13,22,24,26]}\) In addition, a recent study showed the relevance of weight reduction for the reduction of both AF related symptoms and LA dimensions.\(^{[26]}\) Thus, our study and the available evidence underscore the importance of weight loss in patients with symptomatic AF. Interestingly, diabetes seems to have a detrimental effect on LA volume that is independent of obesity.\(^{[27,28]}\) Diabetes has been associated with inflammatory processes, cardiac fibrosis and diastolic dysfunction, which in turn may promote LA remodeling and atrial arrhythmogenicity independent of body fat.\(^{[4,28]}\)

Natriuretic peptides are strong and independent predictors of incident AF and subsequent outcomes.\(^{[5,29–31]}\) Two smaller studies have suggested correlations between NT-proBNP and LA volume among AF patients undergoing CA.\(^{[31,32]}\) Our study expands those findings to a broader AF population, and implicates that NT-proBNP may not only be a marker for heart failure, but also a useful surrogate for LA volume estimation in patients with AF. In addition, our results suggest that renal function is independently associated with LA volume in AF patients, which to our knowledge has not been shown yet, and which may be related to fluid retention in individuals with worse renal function.

Patients undergoing ECV had a larger LA volume compared to CA patients, independent of AF duration and the patient's age. This finding is potentially attributable to a persistently elevated heart rate, a depressed left ventricular function and higher prevalence of underlying structural heart disease; underscoring the importance of aggressively managing risk factors and co-morbidities in AF patients.

One of the key findings of our analyses is that age and hypertension, which are important risk factors for LA enlargement or incident AF in the general population, may not independently influence LA volume and remodelling in AF patients.\(^{[1,11,12,33]}\) These contrasting findings might emphasize the complex pathophysiology of LA enlargement. While in individuals without AF, age and hypertension may be important drivers of LA remodelling, other factors seem to be more important in individuals with AF whose LAs presumably already have undergone a significant remodelling process. These factors are highlighted in the current study and include BMI, metabolic profile and renal function, all of which are associated with volume overload, adverse hemodynamic changes, autonomic dysfunction, higher levels of pro-inflammatory cytokines and a stimulated renin-aldosterone-angiotensin-system.\(^{[4,12,22,24,26–28,34–36]}\) In this context, our data do certainly not mean that blood pressure control should be neglected in AF patients.

There are limitations of this study that deserve mentioning. First, certain patients were in AF while RT3DE was acquired; however, this technology is not thoroughly validated for assessment of cardiac function and structure during AF.\(^{[18–20,37]}\) But, given the superior reproducibility of RT3DE over time in contrast to conventional 2D methods in sinus rhythm, it is plausible that the same is true in patients with AF.\(^{[18–20,37,38]}\) Second, our results do apply to patients with AF, and generalizability to those without AF remains unclear. Third, aging plays an important role in the context of AF development and the mean age of our patients was
rather low. It is therefore unknown, if our results are also applicable to older patients with AF. Finally, the cross-sectional study design does not allow drawing any causal inferences.

Conclusions
Using RT3DE, we found that in patients with AF, the most important correlates with LA volume are sex, body surface area, diabetes, renal function and NT-proBNP. Age and hypertension might play a less important role in this context. These results may help to understand the pathophysiology of LA enlargement and define targeted intervention strategies in AF patients.

Supporting Information
S1 Fig. Assessment of independent determinants of left atrial volume in AF patients—Analysis excluding the cohort factor. SE = Standard error; SD = Standard deviation; y/n = yes / no; AF = Atrial fibrillation; NT-proBNP = N-terminal-pro B-type natriuretic peptide; eGFR = Estimated glomerular filtration rate. R2 is reported for the final multivariable model. The β (95% confidence intervals) represents the increase or decrease in left atrial volume (mL) per unit change of the specific covariate. The multivariable model also included age, resting heart rate, left ventricular ejection fraction, left ventricular mass, high-sensitivity troponin T ≥15ng/mL, interleukin-6, history of heart failure, arterial hypertension, moderate or severe mitral regurgitation and sleep apnea syndrome. All above presented variables selected by the stepwise backward regression model were significant at the ≤0.05 level. † log-transformed variables. ‡ Estimated by the CKD-EPI formula including creatinine and cystatin C. (TIF)

S1 Table. Associations between left atrial volume and various variables in univariate analyses. AF = Atrial fibrillation; y/n = yes / no; PVI = Pulmonary vein isolation; bpm = beat per minute; ECV = Electrical cardioversion; MR = Mitral regurgitation; NT-proBNP = N-terminal-pro B-type natriuretic peptide; eGFR = Estimated glomerular filtration rate. The β (95% confidence intervals) represents the increase or decrease in left atrial volume (mL) per unit change of the specific covariate. † Paroxysmal and persistent AF were found in 95 and 115 patients, respectively. ‡ Emphasizes any minor or major stroke in the past. ¶ The estimated glomerular filtration rate was calculated by using the creatinine and cystatin based CKD-EPI formula. †† log-transformed variables. (DOCX)

Author Contributions
Conceptualization: MB RK DC.
Data curation: MB TH AZ SA KP NH BK GP DC.
Formal analysis: MB PK SA DC.
Funding acquisition: DC.
Investigation: MB TH AZ SA KP AK FS NH BK GP MK DC.
Methodology: MB RK BK DC.
Project administration: SO BK MK DC.
Resources: CS SO BK GP MK DC.
Software: MB BK.
Supervision: DC.
Validation: MB TH AZ SA.
Visualization: MB.
Writing – original draft: MB RK DC.
Writing – review & editing: TH AZ SA PK AK FS NH GP CS SO BK GP MK.

References
1. European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, Kirchhof P, Lip GY, et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31: 2369–2429. doi: 10.1093/eurheartj/ehq278 PMID: 20802247
2. Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, et al. (2011) Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 305: 2086–2087. doi: 10.1001/jama.2011.659 PMID: 21610240
3. Holt BD (2014) Left atrial size and function: role in prognosis. J Am Coll Cardiol 63: 493–505. doi: 10.1016/j.jacc.2013.10.055 PMID: 24291276
4. Dzeshka MS, Lip GY, Snezhitsky V, Shantsila E (2015) Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. J Am Coll Cardiol 66: 943–959. doi: 10.1016/j.jacc.2015.06.1313 PMID: 26293766
5. Liombart V, Antolin-Fontes A, Bustamante A, Giralt D, Rost NS, et al. (2015) B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. Stroke 46: 1187–1195. doi: 10.1161/STROKEAHA.114.008311 PMID: 25765726
6. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, et al. (2006) Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 47: 2357–2363. doi: 10.1016/j.jacc.2006.02.048 PMID: 16781359
7. Parkash R, Green MS, Kerr CR, Connolly SJ, Klein GJ, et al. (2004) The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. Am Heart J 148: 649–654. doi: 10.1016/j.ahj.2004.04.029 PMID: 15459596
8. Bouzas-Mosquera A, Brouillon FJ, Alvarez-Garcia N, Mendez E, Peteiro J, et al. (2011) Left atrial size and risk for all-cause mortality and ischemic stroke. CMAJ 183: E657–664. doi: 10.1503/cmaj.091688 PMID: 21609990
9. Gupta S, Matulievicis SA, Ayers CR, Berry JD, Patel PC, et al. (2013) Left atrial structure and function and clinical outcomes in the general population. Eur Heart J 34: 278–285. doi: 10.1093/eurheartj/ehs188 PMID: 22782941
10. Gupta DK, Shah AM, Giugliano RP, Ruff CT, Antman EM, et al. (2014) Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J 35: 1457–1465. doi: 10.1093/eurheartj/ehu500 PMID: 24302269
11. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D (1995) Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 92: 835–841. doi: 10.1161/01.cir.92.4.835 PMID: 7641364
12. Conen D, Glynn RJ, Sandhu RK, Tedrow UB, Albert CM (2013) Risk factors for incident atrial fibrillation with and without left atrial enlargement in women. Int J Cardiol 168: 1894–1899. doi: 10.1016/j.ijcard.2012.12.060 PMID: 23333369
13. Gerds T, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, et al. (2002) Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 39: 739–743. doi: 10.1161/hy0302.105683 PMID: 11897755
14. D’Andrea A, Riegler L, Rucco MA, Cocchia R, Scarafile R, et al. (2013) Left atrial volume index in healthy subjects: clinical and echocardiographic correlates. Echocardiography 30: 1001–1007. doi: 10.1111/echo.12217 PMID: 23594028
15. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, et al. (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347: 1834–1840. doi: 10.1056/NEJMoa021375 PMID: 12466507
16. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, et al. (2009) Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 53: 1798–1803. doi: 10.1016/j.jacc.2009.02.022 PMID: 19422987

17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, et al. (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367: 20–29. doi: 10.1056/NEJMoai1114248 PMID: 22762315

18. Rohner A, Brinkert M, Kawei N, Buechel RR, Leibundgut G, et al. (2011) Functional assessment of the left atrium by real-time three-dimensional echocardiography using a novel dedicated analysis tool: initial validation studies in comparison with computed tomography. Eur J Echocardiogr 12: 497–505. doi: 10.1093/ejechocard/jer066 PMID: 21685196

19. Buechel RR, Sommer G, Leibundgut G, Rohner A, Riede F, et al. (2013) Assessment of left atrial functional parameters using a novel dedicated analysis tool for real-time three-dimensional echocardiography: validation in comparison to magnetic resonance imaging. Int J Cardiovasc Imaging 29: 601–608. doi: 10.1007/s10554-012-0127-0 PMID: 23001198

20. Zimmermann AJ, Bossard M, Aeschbacher S, Schoen T, Voellmin G, et al. (2015) Effects of sinus rhythm maintenance on left heart function after electrical cardioversion of atrial fibrillation: implications for tachycardia-induced cardiomyopathy. Can J Cardiol 31: 36–43. doi: 10.1016/j.cjca.2014.10.032 PMID: 25547548

21. Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, et al. (2014) Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur Heart J Cardiovasc Imaging 15: 680–690. doi: 10.1093/ehjci/jet284 PMID: 24451180

22. Wang TJ, Parise H, Levy D, D’Agostino RB, Wolf PA, et al. (2004) Obesity and the risk of new-onset atrial fibrillation. JAMA 292: 2471–2477. doi: 10.1001/jama.293.16.1974-a PMID: 15562125

23. Nichols GA, Reinier K, Chugh SS (2009) Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 32: 1851–1856. doi: 10.2337/dc09-0939 PMID: 19794003

24. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, et al. (2010) The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 55: 2319–2327. doi: 10.1016/j.jacc.2010.02.029 PMID: 20488302

25. Schoen T, Pradhan AD, Albert CM, Conen D (2012) Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am Coll Cardiol 60: 1421–1428. doi: 10.1016/j.jacc.2012.06.030 PMID: 22981550

26. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, et al. (2013) Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310: 2050–2060. doi: 10.1001/jama.2013.280521 PMID: 24240932

27. Asbun J, Villarreal FJ (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47: 693–700. doi: 10.1016/j.jacc.2005.09.050 PMID: 16487830

28. Kadappu KK, Boyd A, Eshoo S, Haluska B, Yeo AE, et al. (2012) Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction? Eur Heart J Cardiovasc Imaging 13: 1016–1023. doi: 10.1093/ehjci/jes084 PMID: 22544873

29. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, et al. (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 120: 1768–1774. doi: 10.1161/CIRCULATIONAHA.109.873265 PMID: 19841297

30. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, et al. (2012) Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 125: 1605–1616. doi: 10.1161/CIRCULATIONAHA.111.038729 PMID: 22374183

31. Solheim E, Off MK, Hoff PI, De Bortoli A, Schuster P, et al. (2012) N-terminal pro-B-type natriuretic peptide level at long-term follow-up after atrial fibrillation ablation: a marker of reverse atrial remodeling and successful ablation. J Interv Card Electrophysiol 34: 129–136. doi: 10.1007/s10840-011-9629-2 PMID: 21993599

32. Hwang HJ, Son JW, Nam BH, Joung B, Lee B, et al. (2009) Incremental predictive value of pre-procedural N-terminal pro-B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation. Clin Res Cardiol 98: 213–218. doi: 10.1007/s00392-009-0744-3 PMID: 19229464

33. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, et al. (2010) A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 31: 1730–1736. doi: 10.1093/eurheartj/ehq146 PMID: 20501475
34. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, et al. (2011) Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123: 2946–2953. doi: 10.1161/CIRCULATIONAHA.111.020982 PMID: 21646496

35. Kadappu KK, Kuncoro AS, Hee L, Aravindan A, Spicer ST, et al. (2014) Chronic kidney disease is independently associated with alterations in left atrial function. Echocardiography 31: 956–964. doi: 10.1111/echo.12503 PMID: 24447093

36. Bansal N, Fan D, Hsu CY, Ordonez JD, Go AS (2014) Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc 3: e001303. doi: 10.1161/JAHA.114.001303 PMID: 25332181

37. Heo R, Hong GR, Kim YJ, Mancina J, Cho IJ, et al. (2015) Automated quantification of left atrial size using three-beat averaging real-time three dimensional Echocardiography in patients with atrial fibrillation. Cardiovasc Ultrasound 13: 38. doi: 10.1186/s12947-015-0032-5 PMID: 26306693

38. Mor-Avi V, Yodwut C, Jenkins C, Kuhl H, Nesser HJ, et al. (2012) Real-time 3D echocardiographic quantification of left atrial volume: multicenter study for validation with CMR. JACC Cardiovasc Imaging 5: 769–777. doi: 10.1016/j.jcmg.2012.05.011 PMID: 22897989